EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction

BACKGROUND: Erlotinib and gefitinib are weak base drugs whose absorption and clinical efficacy may be impaired by concomitant gastric acid suppressive (AS) therapy, yet proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2As) are widely indicated in non-small cell lung cancer (NSCLC...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Kumarakulasinghe, Nesaretnam Barr, Syn, Nicholas, Soon, Yu Yang, Asmat, Atasha, Zheng, Huili, Loy, En Yun, Pang, Brendan, Soo, Ross Andrew
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2016
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5356756/
https://ncbi.nlm.nih.gov/pubmed/27907909
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.13458
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars